Company intelligence / Profile preview

Urigen Pharmaceuticals, Inc.

North Brunswick, New Jersey, United Statesvaneltix.com ↗

Ownership: Private
Development stage: Phase 2

Overview

URG101 demonstrated safety and efficacy for reducing symptoms of pelvic pain and urgency in double-blind placebo-controlled Phase II studies. Some clinical programs appear to be terminated or dormant as of the latest available data.[10]

Therapeutic areas: Men's HealthNephrologyWomen's Health
Modalities: Small moleculesCombination products of approved drugs
Industry: Biotech

Drug pipeline

2 assets

URG501

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

None recently disclosed; historical technology transfer agreements with Vical Incorporated and Genetronics Biomedical Corporation during merger period with Valentis.[9]

Beyond the preview

Go deeper on Urigen Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urigen Pharmaceuticals, Inc..

Explore the full profile